Next-generation drug combination for uncomplicated malaria

Within the broader context of rising antimicrobial resistance, multidrug resistant malaria has emerged in Southeast Asia and markers of partial resistance have been reported in Rwanda. If resistance were to take hold in sub-Saharan Africa, where the malaria burden is highest, it would pose a major threat to malaria control and elimination efforts.

New combination therapies are needed to combat this looming possibility, preferably in a single-dose. Of several promising compounds from MMV’s portfolio known to be fully active against all drug-resistant strains, a promising combination of two or more will be selected that has the best profile and the most extensive clinical data supporting their activity. The combination will then be tested in a Phase II clinical study.

Learn more about antimicrobial resistance and malaria

Learn more about uncomplicated malaria